Welcome to Paid Research Studies




  • Condition:   Adrenocortical Carcinoma
    Interventions:   Drug: Cisplatin plus Etoposide;   Other: Observation or Mitotane
    Sponsor:   Azienda Ospedaliera Spedali Civili di Brescia
    Recruiting

  • Condition:   Adrenocortical Carcinoma
    Intervention:   Drug: Cabozantinib-s-malate
    Sponsor:   Wuerzburg University Hospital
    Recruiting

  • Conditions:   Adrenocortical Carcinoma;   Peritoneal Carcinomatosis
    Interventions:   Drug: Cisplatin;   Drug: Sodium thiosulfate;   Procedure: Cytoreductive surgery
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   ENSAT Stage I Adrenal Cortex Carcinoma;   ENSAT Stage II Adrenal Cortex Carcinoma;   ENSAT Stage III Adrenal Cortex Carcinoma
    Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Mitotane;   Procedure: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Amercian Australian Asian Adrenal Alliance (A5);   European Network for the Study of Adrenal Tumors (ENS@T)
    Recruiting

  • Conditions:   Metastatic Carcinoma in the Adrenal Cortex;   Stage III Adrenal Cortex Carcinoma AJCC v8;   Stage IV Adrenal Cortex Carcinoma AJCC v8;   Unresectable Adrenal Cortex Carcinoma
    Interventions:   Drug: Cabozantinib;   Other: Pharmacogenomic Study;   Other: Pharmacokinetic Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adrenal Incidentaloma;   Adrenocortical Carcinoma
    Intervention:  
    Sponsors:   University Medical Center Groningen;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   Radboud University;   Leiden University Medical Center;   Maastricht University Medical Center;   UMC Utrecht;   Erasmus Medical Center;   Martini Hospital Groningen;   Canisius-Wilhelmina Hospital;   Diakonessenhuis, Utrecht;   Isala;   Haga Hospital;   St. Antonius Hospital;   Kennemer Gasthuis;   Maxima Medical Center;   Medical Center Alkmaar;   Medical Centre Leeuwarden;   Meander Medical Center;   Medisch Spectrum Twente;   Onze Lieve Vrouwe Gasthuis;   Rijnstate Hospital;   Elisabeth-TweeSteden Ziekenhuis;   Tergooi Hospital;   Vlietland Ziekenhuis;   Scheper Hospital;   Flevo Hospital
    Recruiting

  • Conditions:   Genitourinary Cancer;   Adrenocortical Carcinoma;   Non-urothelial Bladder;   Non-urothelial Upper Tract;   Penile Cancer;   Non-adenocarcinoma Prostate Cancer;   Refractory Germ-cell
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Colorectal Cancer;   Pancreatic Adenocarcinoma;   Gastric Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Bladder Cancer;   Melanoma;   Ovarian Cancer;   Adrenocortical Cancer;   Breast Cancer;   Other Cancer
    Intervention:  
    Sponsor:   Quantgene Inc.
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Solid Tumors (Part A/B/C/D);   Non-small Cell Lung Cancer (Part E);   Melanoma (Part E);   Squamous Cell Cancer of the Head and Neck (Part E);   Triple Negative Breast Cancer (Part F);   Adrenocortical Carcinoma (Part G);   Mesothelioma (Part G);   High-circulating Myeloid-derived Suppressor Cells (Part H)
    Interventions:   Drug: IPI-549;   Drug: Nivolumab
    Sponsor:   Infinity Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Carcinoma of Unknown Primary Origin;   Kidney Medullary Carcinoma;   Malignant Germ Cell Tumor;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Paraganglioma;   Metastatic Penile Carcinoma;   Paraganglioma;   Skin Squamous Cell Carcinoma;   Small Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Solid Neoplasm;   Vascular Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Adrenal Gland Neoplasm
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting